Automata
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 2
- AI for Science Creates Demand for Lab Infrastructure
A 36氪 人工智能 analysis says OpenAI’s reported acquisition of Orchestra Bio and Anthropic’s disclosed acquisition of Mithril Medicine show model companies moving into biomedical R&D workflows. It identifies three infrastructure opportunities: AI-assisted contract research organizations for experimental validation, laboratory operating systems for automating workflows and scheduling, and scientific-data platforms that preserve experimental context. The report cites Adaptyv, Automata and Transfyr as examples. It also notes that a Google DeepMind and MIT FutureTech survey of 637 US and UK researchers found nearly 50% use AI daily and about 41% are burdened by a backlog of unvalidated hypotheses.
36氪 人工智能 · 🔥 0 - Danaher to launch AI autonomous lab with up to 8x faster antibody reagent development
Danaher announced it will launch its first AI-powered autonomous research lab, based at its reagent subsidiary Abcam and combining AI, robotics and technologies from subsidiaries including Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies and Molecular Devices, with instrument coordination and robotic automation co-developed with Automata, which Danaher invested in during January 2026; full-scale operation is expected in early 2027. In the loop, AI first designs affinity reagents such as antibodies that bind biological targets, robots build and test them, and results are fed back to the models to improve the next design round. Danaher says the approach can speed up the path from concept to validated reagent by up to 8x and lift annual reagent output up to 10x, from dozens to hundreds of reagents — figures that are the company's own projections.
科技新报 · 🔥 0
Experience and discussion from the community
Share my Automata experienceAsk about Automata
Nobody has shared their experience with Automata yet.